After years of underperformance, value stocks finally outshone their expensive growth counterparts in 2022. In fact, value stocks have just enjoyed their strongest 12-month period relative to growth in 21 years, according to Ben Inker of GMO, the fund giant founded by renowned investor Jeremy Grantham.
This trend is unlikely to end any time soon, says Inker.
Value stocks didn’t actually make money in 2022 – it’s more that growth stocks suffered an annus horribilis.
Importantly, the most expensive US growth stocks still look pricey relative to the rest of the market. They peaked out trading around four times the valuation of the average company, says Inker, and are now trading around three times – “still one of the more extreme valuations of the last 40 years”.
Students must learn to be more than mindless ‘machine-minders’
A Communion in the house? Your child’s first chance to learn about money
I’m in my 70s and have €500,000 in savings. If I need to go into a nursing home, what happens if I run out of money?
Microsoft emphasises commitment to Ireland, which can ‘count on us’
Relative to history, the valuation differential between growth and value stocks remains marked in every region of the world, particularly in Europe. GMO’s conclusion: buy value, keep avoiding growth.
Even after a good run, value is “still priced for significant outperformance everywhere”.
